Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer

 Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation for MET-Mutated Advanced Non-Small Cell Lung Cancer

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma

Shots:

  • The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology
  • The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints
  • Capmatinib (INC280) is an oral potent and selective MET inhibitor with expected regulatory submission in Q4’19. In 2009, Novartis signed an exclusive development and commercialization agreement with Incyte for Capmatinib

Click here to­ read full press release/ article | Ref: Novartis | Image: Wall Street Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post